HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

NTRC 0066-0

a small molecule inhibitor of spindle assembly checkpoint kinase TTK (Mps1)

Networked: 3 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 4 or More Rings Heterocyclic Compounds
    - NTRC 0066-0: 3

Experts

1.	Buijsman, Rogier C: 2 articles (11/2017 - 06/2017)
2.	Libouban, Marion A A: 2 articles (11/2017 - 06/2017)
3.	Uitdehaag, Joost C M: 2 articles (11/2017 - 06/2017)
4.	Zaman, Guido J R: 2 articles (11/2017 - 06/2017)
5.	de Man, Jos: 2 articles (11/2017 - 06/2017)
6.	de Roos, Jeroen A D M: 2 articles (11/2017 - 06/2017)
7.	Prinsen, Martine B W: 1 article (11/2017)
8.	Dylus, Jelle: 1 article (06/2017)
9.	Mainardi, Sara: 1 article (06/2017)
10.	Medema, René H: 1 article (06/2017)

Related Diseases

1.	Neoplasms (Cancer) 06/13/2017 - "We show that treatment of tumor cells with the selective small molecule TTK inhibitor NTRC 0066-0 overrides the mitotic checkpoint, irrespective of cell line sensitivity. " 10/01/2015 - "NTRC 0066-0 inhibits tumor growth in MDA-MB-231 xenografts as a single agent after oral application. " 10/01/2015 - "Our studies show that combination of NTRC 0066-0 with a therapeutic dose of docetaxel resulted in doubling of mouse survival and extended tumor remission, without toxicity. " 11/01/2017 - "Cell lines harboring activating mutations in the CTNNB1 gene, encoding the Wnt pathway signaling regulator β-catenin, were on average up to five times more sensitive to TTK inhibitors than cell lines wild-type for CTNNB1 The association of CTNNB1-mutant status and increased cancer cell line sensitivity to TTK inhibition was confirmed with isogenic cell line pairs harboring either mutant or wild-type CTNNB1 Treatment of a xenograft model of a CTNNB1-mutant cell line with the TTK inhibitor NTRC 0066-0 resulted in complete inhibition of tumor growth. "
2.	Colorectal Neoplasms (Colorectal Cancer) 06/13/2017 - "Finally, we confirm that the reference compound reversine is a TTK inhibitor and like NTRC 0066-0, inhibits the proliferation of patient-derived colorectal cancer organoids. "
3.	Aneuploidy (Aneuploid) 06/13/2017 - "In stable aneuploid cells NTRC 0066-0 induced acute CIN, whereas in cells with high levels of pre-existing CIN there was only a small additional fraction of cells mis-segregating their chromosomes. "

Related Drugs and Biologics

1.	Docetaxel (Taxotere)
2.	Catenins
3.	2- (4- morpholinoanilino)- 6- cyclohexylaminopurine